Literature DB >> 27730569

Combined Lower Limb Revascularisation and Supervised Exercise Training for Patients with Peripheral Arterial Disease: A Systematic Review of Randomised Controlled Trials.

Annelise L Menêses1, Raphael M Ritti-Dias2, Belinda Parmenter3, Jonathan Golledge4,5, Christopher D Askew6.   

Abstract

BACKGROUND: Both revascularisation and supervised exercise training improve functional outcomes and quality of life in patients with peripheral arterial disease (PAD). However, the value of combined therapy, where exercise therapy is delivered as an adjunct to revascularisation, is less clear.
OBJECTIVE: To systematically review evidence on the efficacy of lower limb revascularisation combined with supervised exercise training in patients with PAD.
METHODS: Parallel-group randomised controlled trials indexed in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Scopus, CINAHL, SPORTDiscus and Web of Science were searched (up to Jan 2016). Outcome measures were pain-free and maximum walking distances, ankle-brachial index (ABI), leg blood flow and quality of life. Methodological quality was assessed using the Physiotherapy Evidence Database (PEDro) scale. RESULT: Eight trials were included that enrolled a total of 726 patients (mean age 66 ± 3 years, ABI 0.66 ± 0.05). Combined therapy led to greater improvements in pain-free (mean difference [MD] range 38-408 m) and maximal walking distances (MD range 82-321 m) compared with revascularisation or supervised training alone. Combined therapy had no added effect on resting ABI over revascularisation (MD range -0.05 to 0.13), and had a significantly greater effect than supervised exercise training alone (MD range 0.13-0.31). Limited evidence (one to three trials) also suggested that combined therapy led to greater improvements in leg blood flow and physical domains of quality of life than supervised exercise training alone, and that improvements in leg blood flow, as well as the physical and mental domains of quality of life were not different to that achieved with revascularisation alone.
CONCLUSION: Current evidence suggests that PAD patients treated with combined therapy achieve greater functional benefits than those treated with revascularisation or supervised exercise training alone. Limited evidence also suggests that the effect of combined therapy on leg haemodynamics and quality of life may be superior to supervised exercise training alone, and similar to revascularisation alone.

Entities:  

Mesh:

Year:  2017        PMID: 27730569     DOI: 10.1007/s40279-016-0635-5

Source DB:  PubMed          Journal:  Sports Med        ISSN: 0112-1642            Impact factor:   11.136


  64 in total

1.  Reliability of the PEDro scale for rating quality of randomized controlled trials.

Authors:  Christopher G Maher; Catherine Sherrington; Robert D Herbert; Anne M Moseley; Mark Elkins
Journal:  Phys Ther       Date:  2003-08

2.  Patterns of ambulatory activity in subjects with and without intermittent claudication.

Authors:  Andrew W Gardner; Polly S Montgomery; Kristy J Scott; Azhar Afaq; Steve M Blevins
Journal:  J Vasc Surg       Date:  2007-10-24       Impact factor: 4.268

3.  Society for Vascular Surgery Practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction.

Authors:  Michael S Conte; Frank B Pomposelli
Journal:  J Vasc Surg       Date:  2015-02-23       Impact factor: 4.268

4.  Additional supervised exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: a randomized clinical trial.

Authors:  Lotte M Kruidenier; Saskia P Nicolaï; Ellen V Rouwet; Ron J Peters; Martin H Prins; Joep A W Teijink
Journal:  J Vasc Interv Radiol       Date:  2011-05-14       Impact factor: 3.464

5.  Effects of 12 Weeks of Supervised Exercise After Endovascular Treatment: A Randomized Clinical Trial.

Authors:  Elisabeth Bø; Astrid Bergland; Einar Stranden; Jørgen J Jørgensen; Gunnar Sandbaek; Ole Jørgen Grøtta; Jonny Hisdal
Journal:  Physiother Res Int       Date:  2014-12-02

6.  Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for intermittent claudication due to femoropopliteal arterial disease.

Authors:  F A K Mazari; J A Khan; D Carradice; N Samuel; M N A Abdul Rahman; S Gulati; H L D Lee; T A Mehta; P T McCollum; I C Chetter
Journal:  Br J Surg       Date:  2011-10-21       Impact factor: 6.939

7.  Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States.

Authors:  Elizabeth M Mahoney; Kaijun Wang; Hong H Keo; Sue Duval; Kim G Smolderen; David J Cohen; Gabriel Steg; Deepak L Bhatt; Alan T Hirsch
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-10-12

8.  Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis.

Authors:  A W Gardner; E T Poehlman
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272

9.  The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease.

Authors:  R M Greenhalgh; J J F Belch; L C Brown; P A Gaines; L Gao; J A Reise; S G Thompson
Journal:  Eur J Vasc Endovasc Surg       Date:  2008-12       Impact factor: 7.069

Review 10.  Exercise for intermittent claudication.

Authors:  Risha Lane; Brian Ellis; Lorna Watson; Gillian C Leng
Journal:  Cochrane Database Syst Rev       Date:  2014-07-18
View more
  2 in total

Review 1.  Exercise-Induced Vascular Adaptations under Artificially Versus Pathologically Reduced Blood Flow: A Focus Review with Special Emphasis on Arteriogenesis.

Authors:  Johanna Vogel; Daniel Niederer; Georg Jung; Kerstin Troidl
Journal:  Cells       Date:  2020-01-31       Impact factor: 6.600

Review 2.  Evidence-Based Recommendations for Medical Management of Peripheral Artery Disease.

Authors:  Jonathan Golledge; Aaron Drovandi
Journal:  J Atheroscler Thromb       Date:  2021-03-21       Impact factor: 4.928

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.